e-Therapeutics has teamed up with AI experts Intellegens and Biorelate to improve its technology for computer-based drug discovery.
Based in Oxford, e-Therapeutics has the mission of reducing the time and money it costs to develop new drugs with the help of artificial intelligence. Its platform can explore large amounts of public and private databases to model complex diseases and select the most promising compounds to treat them.
In order to boost its prediction power, the company has signed two new partnerships. One with Intellegens, a spin-out from the University of Cambridge with a “unique AI method” to work with incomplete data. e-Therapeutics expects this technology to help it predict and correct errors in large-scale biological and chemical data.
The other partnership involves Biorelate, based in Manchester. This company employs AI to analyze and dig out relevant information from scientific literature. e-Therapeutics plans to feed this information directly into its drug discovery technology.
The application of AI to drug discovery is a growing trend, especially in the UK. Companies like BenevolentBIO in London and Exscientia in Oxford are already starting to sign deals with big pharma to speed drug discovery through AI.
Images via Phonlamai Photo /Shutterstock